ACM
XERS icon

Aster Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Aster Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-687
Closed -$3.77K – 1292
2026
Q1 		$3.77K Buy
+687
New +$4.55K ﹤0.01% 703
2025
Q3 		– Sell
-1,067
Closed -$4.98K – 1416
2025
Q2 		$4.98K Buy
+1,067
New +$4.89K ﹤0.01% 863

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Aster Capital Management's XERS Position: Q2 2026 in Review

Aster Capital Management sold out of Xeris Biopharma Holdings (XERS) in Q2 2026, closing a stake of 687 shares — an estimated $3.77K sold.

Aster Capital Management first reported a position in XERS in Q2 2025 and held it in 2 quarters. The position peaked at $4.98K in Q2 2025. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Aster Capital Management reported no remaining Xeris Biopharma Holdings position as of Q2 2026 after selling out during the quarter.
  • Aster Capital Management sold 687 Xeris Biopharma Holdings shares in Q2 2026, an estimated $3.77K.
  • Aster Capital Management first reported a position in Xeris Biopharma Holdings in Q2 2025 and held it in 2 quarters.
  • Aster Capital Management's Xeris Biopharma Holdings position peaked at $4.98K in Q2 2025.
  • 240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.